
The U.S. Department of Justice has filed a civil action against Vohra Wound Physicians Management, alleging various schemes to submit false claims for payment to Medicare. Learn more about the ongoing lawsuit and how Health Law Alliance supports wound care providers to avoid legal scrutiny.
On April 4, 2025, the Department of Justice initiated a civil action against Vohra Wound Physicians Management LLC (“Vohra”), one of the largest specialty wound care providers in the nation, alleging multiple violations of the False Claims Act. The lawsuit alleges that Vohra and its founder, Dr. Ameet Vohra, engaged in a complex scheme to overbill Medicare for debridement procedures, many of which were allegedly not performed or were not medically necessary.
In its complaint, the DOJ alleges wide-ranging efforts to overbill for debridement procedures across the Practice’s locations, including the use of a proprietary EMR system that automatically billed debridement procedures as the highest-reimbursing type of procedure, regardless of procedure type. The system allegedly inserted false clinical observations into patient charts, using pre-programmed text to create the false impression that surgical procedures were performed to evade audit scrutiny. The DOJ further alleged that Vohra intentionally failed to educate its physicians, who were not wound specialists by training, about the different types of debridement procedures and corresponding Medicare payment rules during training, pressuring physicians to perform as many debridements as possible through aggressive revenue goals and targets.
Enhanced Regulatory Oversight: Key Takeaways for Wound Care Providers
The lawsuit is a reminder of the increasing legal and regulatory scrutiny facing providers in 2025. Just last year, CMS initiated a “clawback” initiative aimed at recouping overpayments to providers with a particular emphasis on wound care procedures, citing high rates of incomplete or insufficient documentation and coding errors as common issues. In particular, OIG has signaled its intent to increase its oversight into wound care providers’ billing. In November 2024, OIG announced it would be dedicating significant resources to review Part B payments for skin substitute claims as part of its Work Plan.
While wound care has long been a target of federal enforcement activity, wound care practice continues to rapidly evolve, particularly as the aging population increases and new technologies arise. 2025 has already begun to see more widespread federal investigation of wound care practices, meaning wound care providers are under more pressure now than ever before—facing audits, investigations, and even civil and criminal penalties.
Your Partners in Navigating Wound Care’s Changing Landscape
Successfully navigating a complex regulatory environment requires expert legal guidance. With decades of experience helping providers navigate audits, minimize their financial exposure, and defend against overpayment allegations, our team partners with you to address the challenges facing your practice and help ensure your practice is prepared for any situation.
MORE ARTICLES BY CATEGORY
Italian Gold Broker Criminally Charged in $86 Million Customs Duty and Tariff Evasion Scheme Released on Bail
Italian national Claudio Fogale was released from federal jail after his attorney, Anthony J. Mahajan, successfully argued that the evidence was weak and legal requirements were ambiguous.
Read More >>PBM Enforcement Trends Independent Pharmacies Must Prepare for in 2026
Independent pharmacies are heading into 2026 under tighter PBM oversight, more aggressive audit practices, and evolving reimbursement models driven by regulatory pressure and DIR fee reform. To survive in this environment, pharmacies must strengthen compliance, documentation, and inventory controls while partnering with experienced PBM counsel to manage audits, protect reimbursements, and avoid network termination.
Read More >>PBM Audit Triggers: Understanding How Prescription Activity Is Evaluated
Pharmacy benefit managers (PBMs) increasingly use data analytics and algorithmic surveillance to identify “red flag” prescriptions and atypical dispensing patterns, which can trigger audits, recoupments, network terminations, and payment withholds for independent pharmacies. By understanding common PBM risk indicators and implementing strong compliance practices, internal audits, documentation, and timely legal support, pharmacies can reduce exposure and more effectively defend themselves during PBM reviews and appeals.
Read More >>Health Law Alliance Successfully Reverses OptumRx’s Network Termination for a Michigan Pharmacy
We are proud to announce that the Health Law Alliance has successfully reversed a network termination from OptumRx for a Michigan-based independent pharmacy.
Read More >>






